LBCL-话题@MedSci

#LBCL#

54篇内容 | 2336人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2021268, encodeId=8fee20212681f, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood Cancer J：大剂量甲氨蝶呤可有效预防DLBCL患者孤立性CNS复发, objectType=article, longId=216228, objectId=5cf7216228e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cf7216228e4, replyNumber=0, likeNumber=101, createdTime=2022-07-11, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cf7216228e4, moduleTitle=Blood Cancer J：大剂量甲氨蝶呤可有效预防DLBCL患者孤立性CNS复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cf7216228e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021259, encodeId=e50c20212599c, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=J Clin Oncol：简化版老年患者评估量表在DLBCL老年患者中的应用, objectType=article, longId=207491, objectId=1c6c20e49130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c6c20e49130, replyNumber=0, likeNumber=81, createdTime=2022-01-05, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c6c20e49130, moduleTitle=J Clin Oncol：简化版老年患者评估量表在DLBCL老年患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c6c20e49130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021260, encodeId=175820212605b, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, objectType=article, longId=207552, objectId=b86b20e552cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b86b20e552cf, replyNumber=0, likeNumber=68, createdTime=2022-01-29, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b86b20e552cf, moduleTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b86b20e552cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021262, encodeId=46842021262ae, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性, objectType=article, longId=210513, objectId=1f42210513fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f42210513fc, replyNumber=0, likeNumber=111, createdTime=2021-06-26, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f42210513fc, moduleTitle=J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f42210513fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021258, encodeId=a171202125825, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=J Clin Oncol：R-CHOP方案+来那度胺可进一步改善新确诊DLBCL患者预后, objectType=article, longId=207043, objectId=91d820e04381, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91d820e04381, replyNumber=0, likeNumber=97, createdTime=2021-02-18, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91d820e04381, moduleTitle=J Clin Oncol：R-CHOP方案+来那度胺可进一步改善新确诊DLBCL患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91d820e04381)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021255, encodeId=ef662021255a6, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：阿托珠单抗用于初治的aaIPI≥1的DLBCL患者的疗效不优于利妥昔单抗, objectType=article, longId=204528, objectId=c65320452846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c65320452846, replyNumber=0, likeNumber=90, createdTime=2021-07-08, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c65320452846, moduleTitle=Blood：阿托珠单抗用于初治的aaIPI≥1的DLBCL患者的疗效不优于利妥昔单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c65320452846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021267, encodeId=3dcc202126e32, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=瑞基仑赛（Relma-cel）对于R/R DLBCL患者表现出突破性疗效, objectType=article, longId=214742, objectId=fde0214e427b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde0214e427b, replyNumber=0, likeNumber=81, createdTime=2021-08-29, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde0214e427b, moduleTitle=瑞基仑赛（Relma-cel）对于R/R DLBCL患者表现出突破性疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde0214e427b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021266, encodeId=04332021266de, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Int J Clin Oncol：tisagenlecleucel可有效且安全的治疗某些特定的日本R/R DLBCL患者, objectType=article, longId=212391, objectId=3ae121239168, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ae121239168, replyNumber=0, likeNumber=83, createdTime=2022-04-16, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ae121239168, moduleTitle=Int J Clin Oncol：tisagenlecleucel可有效且安全的治疗某些特定的日本R/R DLBCL患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ae121239168)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021263, encodeId=4a9b202126339, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！, objectType=article, longId=210699, objectId=0bbd21069923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbd21069923, replyNumber=0, likeNumber=99, createdTime=2021-10-19, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbd21069923, moduleTitle=J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bbd21069923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021256, encodeId=f2db202125613, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, objectType=article, longId=206207, objectId=df2920620e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2920620e11, replyNumber=0, likeNumber=64, createdTime=2021-12-14, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2920620e11, moduleTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2920620e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021264, encodeId=6934202126464, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, objectType=article, longId=211283, objectId=6e722112837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e722112837b, replyNumber=0, likeNumber=0, createdTime=2022-02-03, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e722112837b, moduleTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e722112837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021261, encodeId=bb602021261e3, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, objectType=article, longId=209158, objectId=40ec209158b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ec209158b9, replyNumber=0, likeNumber=81, createdTime=2021-06-08, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ec209158b9, moduleTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ec209158b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021257, encodeId=552e202125ee4, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？, objectType=article, longId=206361, objectId=420e206361f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=420e206361f1, replyNumber=0, likeNumber=92, createdTime=2021-05-07, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=420e206361f1, moduleTitle=J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=420e206361f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021251, encodeId=63432021251a6, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：piRNA-30473通过调节m6A RNA甲基化促进DLBCL发生和预后不良, objectType=article, longId=201201, objectId=2be1201201f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be1201201f5, replyNumber=0, likeNumber=74, createdTime=2021-08-25, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be1201201f5, moduleTitle=Blood：piRNA-30473通过调节m6A RNA甲基化促进DLBCL发生和预后不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be1201201f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021250, encodeId=9f442021250aa, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：PET-CT指导性巩固放疗对晚期DLBCL患者长期预后的影响, objectType=article, longId=200532, objectId=ac7a200532c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac7a200532c2, replyNumber=0, likeNumber=104, createdTime=2020-10-13, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac7a200532c2, moduleTitle=Blood：PET-CT指导性巩固放疗对晚期DLBCL患者长期预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac7a200532c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021247, encodeId=6eb9202124eb6, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：根据基因表达亚群将DLBCL分成新的亚型, objectType=article, longId=187423, objectId=574e18e423b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574e18e423b2, replyNumber=0, likeNumber=68, createdTime=2020-09-22, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574e18e423b2, moduleTitle=Blood：根据基因表达亚群将DLBCL分成新的亚型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=574e18e423b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021254, encodeId=01b4202125491, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？, objectType=article, longId=203318, objectId=3485203318ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3485203318ee, replyNumber=0, likeNumber=58, createdTime=2021-02-05, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3485203318ee, moduleTitle=Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3485203318ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021253, encodeId=7d0c2021253e3, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制, objectType=article, longId=203317, objectId=5a9020331ec1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a9020331ec1, replyNumber=0, likeNumber=57, createdTime=2021-07-05, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a9020331ec1, moduleTitle=Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a9020331ec1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021252, encodeId=f95020212520e, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Ann Hematol：异基因干细胞移植可有效治疗DLBCL, objectType=article, longId=201788, objectId=4e94201e8841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e94201e8841, replyNumber=0, likeNumber=81, createdTime=2021-01-11, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e94201e8841, moduleTitle=Ann Hematol：异基因干细胞移植可有效治疗DLBCL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e94201e8841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021243, encodeId=4427202124300, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：用钙调神经磷酸酶抑制剂治疗DLBCL, objectType=article, longId=184254, objectId=332a184254df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=332a184254df, replyNumber=0, likeNumber=0, createdTime=2020-10-26, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=332a184254df, moduleTitle=Blood：用钙调神经磷酸酶抑制剂治疗DLBCL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=332a184254df)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

LBCL

2020-05-29

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood Cancer J：大剂量甲氨蝶呤可有效预防DLBCL患者孤立性CNS复发

2022-07-11

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

J Clin Oncol：简化版老年患者评估量表在DLBCL老年患者中的应用

2022-01-05

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS

2022-01-29

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性

2021-06-26

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

J Clin Oncol：R-CHOP方案+来那度胺可进一步改善新确诊DLBCL患者预后

2021-02-18

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：阿托珠单抗用于初治的aaIPI≥1的DLBCL患者的疗效不优于利妥昔单抗

2021-07-08

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

瑞基仑赛（Relma-cel）对于R/R DLBCL患者表现出突破性疗效

2021-08-29

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Int J Clin Oncol：tisagenlecleucel可有效且安全的治疗某些特定的日本R/R DLBCL患者

2022-04-16

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！

2021-10-19

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）

2021-12-14

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！

2022-02-03

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤

2021-06-08

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？

2021-05-07

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：piRNA-30473通过调节m6A RNA甲基化促进DLBCL发生和预后不良

2021-08-25

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：PET-CT指导性巩固放疗对晚期DLBCL患者长期预后的影响

2020-10-13

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：根据基因表达亚群将DLBCL分成新的亚型

2020-09-22

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？

2021-02-05

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制

2021-07-05

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Ann Hematol：异基因干细胞移植可有效治疗DLBCL

2021-01-11

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：用钙调神经磷酸酶抑制剂治疗DLBCL

2020-10-26

科室
- - 订阅+
  - 更多科室
工具
服务